87 related articles for article (PubMed ID: 19544526)
1. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
Zambelli D; Zuntini M; Nardi F; Manara MC; Serra M; Landuzzi L; Lollini PL; Ferrari S; Alberghini M; Llombart-Bosch A; Piccolo E; Iacobelli S; Picci P; Scotlandi K
Int J Cancer; 2010 Jan; 126(1):41-52. PubMed ID: 19544526
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of LGALS3BP in human colorectal carcinoma.
Piccolo E; Tinari N; D'Addario D; Rossi C; Iacobelli V; La Sorda R; Lattanzio R; D'Egidio M; Di Risio A; Piantelli M; Natali PG; Iacobelli S
J Transl Med; 2015 Jul; 13():248. PubMed ID: 26219351
[TBL] [Abstract][Full Text] [Related]
3. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.
Benini S; Zuntini M; Manara MC; Cohen P; Nicoletti G; Nanni P; Oh Y; Picci P; Scotlandi K
Int J Cancer; 2006 Sep; 119(5):1039-46. PubMed ID: 16570284
[TBL] [Abstract][Full Text] [Related]
5. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
[TBL] [Abstract][Full Text] [Related]
6. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Piccolo E; Tinari N; Semeraro D; Traini S; Fichera I; Cumashi A; La Sorda R; Spinella F; Bagnato A; Lattanzio R; D'Egidio M; Di Risio A; Stampolidis P; Piantelli M; Natoli C; Ullrich A; Iacobelli S
J Mol Med (Berl); 2013 Jan; 91(1):83-94. PubMed ID: 22864925
[TBL] [Abstract][Full Text] [Related]
7. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma.
Baer C; Nees M; Breit S; Selle B; Kulozik AE; Schaefer KL; Braun Y; Wai D; Poremba C
Int J Cancer; 2004 Jul; 110(5):687-94. PubMed ID: 15146558
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
9. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
10. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
[TBL] [Abstract][Full Text] [Related]
11. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention.
Stampolidis P; Ullrich A; Iacobelli S
Oncogene; 2015 Jan; 34(1):39-52. PubMed ID: 24362527
[TBL] [Abstract][Full Text] [Related]
12. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
14. Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness.
Meynet O; Scotlandi K; Pradelli E; Manara MC; Colombo MP; Schmid-Antomarchi H; Picci P; Bernard A; Bernard G
Cancer Res; 2010 May; 70(9):3730-8. PubMed ID: 20388798
[TBL] [Abstract][Full Text] [Related]
15. Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma.
Haga A; Ogawara Y; Kubota D; Kitabayashi I; Murakami Y; Kondo T
Electrophoresis; 2013 Jun; 34(11):1670-8. PubMed ID: 23483572
[TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.
Scotlandi K; Manara MC; Serra M; Marino MT; Ventura S; Garofalo C; Alberghini M; Magagnoli G; Ferrari S; Lopez-Guerrero JA; Llombard-Bosch A; Picci P
Eur J Cancer; 2011 May; 47(8):1258-66. PubMed ID: 21345666
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
[TBL] [Abstract][Full Text] [Related]
18. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.
Ouchida M; Ohno T; Fujimura Y; Rao VN; Reddy ES
Oncogene; 1995 Sep; 11(6):1049-54. PubMed ID: 7566963
[TBL] [Abstract][Full Text] [Related]
19. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
20. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
